Last updated: 2026-09-13 15:37:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cardio Diagnostics Holdings Inc. (CDIO) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $2.06, with a market capitalization of $6.01M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.97 to $7.91. This page covers its latest market performance, valuation, price trends and company information.
$6.01M | |
$2.05 | |
$255.00 | |
$0.97 | |
$1.98 | |
25.12K | |
58.88K | |
-- | |
$7.91 | |
$0.97 | |
-- | |
-- |
Cardio Diagnostics Holdings Inc. (CDIO) last closed at $1.98 as of 2026-09-11 23:31:00, unchanged from the previous close of $1.98.
During the latest regular trading session, CDIO traded between $0.97 and $255.00, with a volume of 25.12K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Cardio Diagnostics Holdings Inc. (CDIO) moved from $1.84 to $2.06, representing a gain of 11.85% ($0.22).
The stock traded between $1.81 and $2.14 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 40.05 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 15.7%
CDIO is currently trading at $2.06, placing it 15.7% of the way from its 52-week low of $0.97 to its 52-week high of $7.91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cardio Diagnostics Holdings Inc. (CDIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.